Brains, Blood, and Beyond 🧠🩸🚀: GLP-1RAs for Mind, Metabolism and Mortality

New Study Alert! 🧠💉📉   Exciting real-world evidence shows that GLP-1 receptor agonists—semaglutide and tirzepatide—not only help with type 2 diabetes and obesity but may also reduce the risk of dementia, stroke, and all-cause mortality! 🙌📊   In a cohort of over 60,000 patients, these agents delivered neuroprotective and cerebrovascular benefits beyond glycemic control. Benefits were especially notable in older adults, women, and those with BMI 30–40. 💪👵🧬   🔗 If you're passionate about brain health, diabetes, and the expanding therapeutic role of GLP-1RAs—this is a must-read!   📄 Published in JAMA Network Open | July 2025 📌 #GLP1 #Semaglutide #Tirzepatide #Dementia #Stroke #Diabetes #Neuroprotection #CardiometabolicHealth #JAMA #RealWorldEvidence #LongevityMedicine